For the Wellness Briefing, Glossy checked in with leaders in the peptide space, including attorney Jeff Cohen, Nuritas founder Dr. Nora Khaldi and CeliaRx founder Koehl Robinson, to unpack the results of last week’s FDA advisory committee meetings. Additionally, Whoop hires Glossier’s former CEO as its chief commercial officer, the AI-powered robotic massage market grows, and skin-care brand Prequel expands its executive team. An FDA committee just took a big step to make peptides more accessible. Here’s what it means for the wellness industry.
Injectable research peptides — including internet-famous BPC-157 and TB-500, which are hailed by influencers and celebrities as cure-alls for injuries and gut issues — are slowly shedding their gray market status.
After months of speculation about the legal future of many popular peptides, the Food and Drug Administration’s Pharmacy Compounding Advisory Committee met last week to vote on widening their availability through deregulation. Specifically, whether or not seven popular peptides should be moved to the “503A bulks list,” which allows compounding pharmacies to make and sell them without legal risk.
Until now, physicians risked losing their license by prescribing certain peptides, and compounding pharmacies risked legal jeopardy for selling them, leaving the market with rampant demand but only gray-market sellers.
